On a deal spree, Mallinckrodt bags Sucampo and two late-stage rare disease drugs for $1.2B
The biotech year is ending with a light bang on the M&A front.
Suffering from a rep based more on exploiting markets than developing new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
